412 filings
Page 6 of 21
8-K
3mei3szfu6030e6ig
22 Feb 22
Regulation FD Disclosure
9:09am
424B3
e693w yhd24lx
2 Feb 22
Prospectus supplement
4:16pm
EFFECT
xggavoh5ql1ydfhm
2 Feb 22
Notice of effectiveness
12:15am
POS EX
2y8jyak
28 Jan 22
Additional exhibits for listing
6:15am
POS AM
kejix1
25 Jan 22
Prospectus update (post-effective amendment)
4:56pm
424B3
72sca 0ge5fp37w89615
19 Jan 22
Prospectus supplement
9:43pm
8-K
xe8v0wfwuv
19 Jan 22
KemPharm Issues Letter to Shareholders Detailing Strategic Focus on CNS/Rare Disease Indications and Updated Clinical Development Strategy
4:27pm
424B3
txoj0mg vn6k
20 Dec 21
Prospectus supplement
7:44am
8-K
dqy xt409jpkgy21
20 Dec 21
KemPharm, Inc. Announces Authorization of $50 Million Share Repurchase Program
7:43am
424B3
zcc7am864y894kpg3
14 Dec 21
Prospectus supplement
8:48am
8-K
wmrx6s
14 Dec 21
Regulation FD Disclosure
8:47am
424B3
x1i9b2tc8fhml2 d93jm
10 Nov 21
Prospectus supplement
5:19pm
424B3
osuwg260
10 Nov 21
Prospectus supplement
5:15pm
8-K
tezdq1v2hckol 7vha
10 Nov 21
KemPharm Reports Third Quarter 2021 Financial Results and Corporate Updates
4:12pm
424B3
ub5 j6trire5d
19 Oct 21
Prospectus supplement
9:27am
8-K
vh8dnh2a3kg63c
19 Oct 21
KemPharm, Inc. Announces Uplisting to The Nasdaq Global Select Market
9:24am
424B3
zrzs59
20 Aug 21
Prospectus supplement
5:04pm
8-K
9p3fz mc3cyq
18 Aug 21
KemPharm Appoints Tamara A. Seymour to Board of Directors
5:01pm
424B3
3w2dza 9isoxo
16 Aug 21
Prospectus supplement
12:00am